Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Income from Continuing Operations (2024 - 2025)

Humacyte has reported Income from Continuing Operations over the past 2 years, most recently at 33389000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 33389000.0 for Q4 2025, down 12.25% from a year ago — trailing twelve months through Dec 2025 was 116763000.0 (up 2.37% YoY), and the annual figure for FY2025 was 116763000.0, up 2.35%.
  • Income from Continuing Operations for Q4 2025 was 33389000.0 at Humacyte, down from 26412000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for HUMA hit a ceiling of 25522000.0 in Q1 2025 and a floor of 33389000.0 in Q4 2025.